Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CERo Therapeutics Holdings, Inc. (CERO) SEC filings page on Stock Titan provides access to the company’s public reports and regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a clinical-stage biotechnology issuer and emerging growth company, CERo uses SEC filings to describe its immunotherapy platform, clinical programs, capital structure, and risk factors in detail.
Key filings for CERO include current reports on Form 8-K, which the company has used to announce material events such as Nasdaq listing determinations, private placements of Series E convertible preferred stock, equity line of credit agreements with institutional investors, and clinical or corporate presentations furnished under Regulation FD. These 8-Ks often provide timely information on financing terms, changes in trading venue, and progress of the CER-1236 program.
CERo’s registration statements on Form S-1 describe arrangements like its committed equity financing with an institutional investor, including the potential resale of large blocks of common stock issued under common stock purchase agreements. These documents outline how the company may raise capital over time and discuss associated risks and dilution considerations.
Other important disclosures include proxy materials on Schedule 14A, which have covered proposals such as a reverse stock split, increases to the 2024 Equity Incentive Plan share reserve, and approvals related to convertible preferred stock. Notifications like Form 12b-25 (NT 10-Q) explain delays in periodic reporting and provide preliminary financial information when applicable.
On this page, Stock Titan surfaces new CERO filings as they appear in the EDGAR system and applies AI to highlight key sections, such as clinical trial plans, financing covenants, listing status updates, and changes to capital structure. Users can quickly locate 10-K, 10-Q, S-1, 8-K, proxy statements, and other forms, while AI summaries help clarify technical language around preferred stock terms, equity lines, and regulatory or listing developments that may affect CERO shareholders.
CERo Therapeutics Holdings has filed a Prospectus Supplement No. 3 (424B3) updating their May 23, 2025 prospectus for 2,100,000 shares of common stock. The company's stock (NASDAQ: CERO) last traded at $9.56 per share, while its warrants (CEROW) traded at $0.0264.
The key development reported is that the FDA has granted Orphan Drug Designation to the company's lead drug candidate CER-1236 for treating acute myeloid leukemia, as announced on June 17, 2025.
As an emerging growth company, CERo Therapeutics trades on the Nasdaq Capital Market. The filing includes important risk disclosures for investors, and the company has not elected to use the extended transition period for complying with new financial accounting standards.
- Common stock par value: $0.0001 per share
- Warrants: Each exercisable for 1/2000th of a common share
- Principal office: South San Francisco, CA